These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30569245)

  • 1. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
    Seitz L; Jin L; Leleti M; Ashok D; Jeffrey J; Rieger A; Tiessen RG; Arold G; Tan JBL; Powers JP; Walters MJ; Karakunnel J
    Invest New Drugs; 2019 Aug; 37(4):711-721. PubMed ID: 30569245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insight into the dual-antagonistic mechanism of AB928 on adenosine A
    Weng Y; Yang X; Zhang Q; Chen Y; Xu Y; Zhu C; Xie Q; Wang Y; Yang H; Liu M; Lu W; Song G
    Sci China Life Sci; 2024 May; 67(5):986-995. PubMed ID: 38319473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
    Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
    Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
    Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.
    Chandorkar G; Zhan Q; Donovan J; Rege S; Patino H
    BMC Pharmacol Toxicol; 2017 Mar; 18(1):24. PubMed ID: 28347318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAGE-217, A Novel GABA
    Hoffmann E; Nomikos GG; Kaul I; Raines S; Wald J; Bullock A; Sankoh AJ; Doherty J; Kanes SJ; Colquhoun H
    Clin Pharmacokinet; 2020 Jan; 59(1):111-120. PubMed ID: 31338688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
    Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
    J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
    Boof ML; Géhin M; Voors-Pette C; Hsin CH; Sippel V; Strasser DS; Dingemanse J
    Br J Clin Pharmacol; 2024 Feb; 90(2):588-599. PubMed ID: 37752659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers.
    Badman MK; Chen J; Desai S; Vaidya S; Neelakantham S; Zhang J; Gan L; Danis K; Laffitte B; Klickstein LB
    Clin Pharmacol Drug Dev; 2020 Apr; 9(3):395-410. PubMed ID: 31823525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the selective A2
    Seifert M; Benmebarek MR; Briukhovetska D; Märkl F; Dörr J; Cadilha BL; Jobst J; Stock S; Andreu-Sanz D; Lorenzini T; Grünmeier R; Oner A; Obeck H; Majed L; Dhoqina D; Feinendegen M; Gottschlich A; Zhang J; Schindler U; Endres S; Kobold S
    Br J Cancer; 2022 Dec; 127(12):2175-2185. PubMed ID: 36266575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H
    Venail F; Attali P; Wersinger E; Gomeni R; Poli S; Schmerber S
    Br J Clin Pharmacol; 2018 Dec; 84(12):2836-2848. PubMed ID: 30152527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, and Pharmacokinetics of the Novel Adenosine A
    Tayama T; Ishiuchi M; Sugiyama K; Oka Y; Maeda H; Nagata Y; Hruska M; Kagawa Y
    Clin Pharmacol Drug Dev; 2023 Aug; 12(8):801-809. PubMed ID: 36683291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
    Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
    Ramanathan S; Di Paolo JA; Jin F; Shao L; Sharma S; Robeson M; Kearney BP
    Clin Drug Investig; 2017 Feb; 37(2):195-205. PubMed ID: 27785737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers.
    Hu Y; Zhang H; Li X; Mai J; Yang L; Yan J; Li Y; Sun J; Xu W; He S; Li J; Wu M
    Expert Opin Investig Drugs; 2022 Sep; 31(9):977-985. PubMed ID: 34633260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
    Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
    Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.